 BOSTON, Dec. 11, 2020 GLOBE NEWSWIRE -- Rhythm Pharmaceuticals, Inc. Nasdaq:RYTM, a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced the appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors. 